Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPiyatida ChumnumsiriwathKNKiran NaqviSGShawn P. Griffin

Discussion

Loading...

Member takes

Overview

Observational analysis found improved progression-free survival with maintenance blinatumomab in adult B-ALL post-transplant, indicating effectiveness of intensified therapy.

Key Points

  • Blinatumomab maintenance is linked to improved outcomes in B-cell acute lymphoblastic leukemia post-allogeneic transplantation.
  • Patients receiving melphalan along with blinatumomab showed significant progression-free survival rates.
  • The observation involved adult B-ALL patients undergoing an intensified regimen combining fludarabine and melphalan.
  • Findings suggest the importance of ongoing maintenance therapy to enhance survival rates after transplantation.

Cite This Study

Chumnumsiriwath et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e52bhttps://doi.org/10.1182/blood-2025-2520
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia2025
  2. 2Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025
  3. 3Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL17312025
  4. 4Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia2025 · 1 citations
  5. 5Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025